onclive.com
Novel therapeutic strategies are poised to expand in adjuvant settings for
patients with early-stage disease facing recurrence risks in the treatment
paradigms for a range of tumor types after positive data from large phase 3
clinical trials were highlighted at the 2021 American Society of Clinical …
almost 4 years ago
onclive.com
The immune checkpoint TIM-3 is shaping up to be a viable target for designing therapies for patients with non–small cell lung cancer and other malignancies.
over 3 years ago
onclive.com
Although molecular biomarkers are becoming increasingly relevant in cancer care,
community oncologists confront a plethora of challenges in translating research
findings into practice.
almost 3 years ago
onclive.com
The menu of tissue-agnostic oncology drug approvals is growing, generating new
treatment options for patients with rare cancers and strengthening the rationale
for broad next-generation sequencing.
over 2 years ago
Media DatabaseFind the right journalists
Online NewsroomShape your own narrative
Press Release CreatorCreate and send press releases
Media MonitoringTrack every single online mention
Media Pitching ToolContact recommendations & stats
PR ReportsShowcase the impact of your work
PR CRMManage contacts in easy way
AI PR SoftwareUse AI to save time on your workflow
Social Media ListeningGet a full overview of your brand's presence